Obese, pregnant
women have exacerbated inflammation and insulin resistance that put them and
their fetus at risk for adverse prenatal outcomes and future
risk of cardiometabolic disease.
Our objective was
to determine the effects of 10 weeks of docosahexaenoic acid (DHA)
supplementation on glucose tolerance and markers of inflammation in healthy,
overweight/obese, pregnant women.
Using a
randomized, double-blind, placebo-controlled trial, 60 women, with a pregravid
body mass index ≥ 25 consumed placebo or DHA (800 mg DHA, algal oil) capsules
for 10 weeks from 26 to 36 weeks gestation.
No comments:
Post a Comment